February 12, 2018 / 6:26 AM / 4 months ago

BRIEF-Asit Biotech FY Net Loss Narrows To ‍​12.0 Million Euros

* FY OPERATING LOSS EUR 12.0 MILLION VERSUS LOSS OF EUR 12.3 MILLION YEAR AGO

* CLINICAL AND RESEARCH AND DEVELOPMENT PROGRAMS ON TRACK WITH MULTIPLE DEVELOPMENT MILESTONES EXPECTED IN 2018‍​

* CASH POSITION AT END-2017 OF €2.13 MILLION‍​

* REDUCTION IN OPERATING EXPENSES IN LINE WITH THE COMPANY’S EXPECTATIONS‍​

* FY NET LOSS EUR ‍​12.0 MILLION VERSUS LOSS OF EUR 12.3 MILLION YEAR AGO

* 2ND PHASE III GP-ASIT+ TRIAL IN EUROPE IN ADULTS WITH SITE SELECTION IN Q4 2018

* FIRST-PATIENT FIRST-VISIT FOR GP-ASIT+ IN Q1 2019‍​ III Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below